Department of Urology, Weill Cornell Medical College, New York, NY.
Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, NY.
Urology. 2020 Jun;140:7-13. doi: 10.1016/j.urology.2020.03.007. Epub 2020 Mar 19.
We performed a systematic review to examine the efficacy and outcomes of Botulinum Toxin A (BoNT-A) as the primary intervention strategy for patients with detrusor external sphincter dyssynergia. Eleven studies were included in the analysis (n = 353; 16% female, 84% male). BoNT-A was effective in 60%-78% of patients for reducing postvoid residual, mean detrusor pressure, detrusor leak point pressure, and mean urethral pressure 1 month after injection. Most patients required reinjection after an average of 4-9 months. BoNT-A was not associated with any significant adverse events, and may improve quality of life, as well as urodynamic parameters for detrusor external sphincter dyssynergia.
我们进行了一项系统评价,以检查肉毒杆菌毒素 A(BoNT-A)作为逼尿肌外括约肌协同失调患者的主要干预策略的疗效和结果。分析中包括 11 项研究(n=353;16%为女性,84%为男性)。BoNT-A 在注射后 1 个月时,有效降低了 60%-78%的患者的残余尿量、平均逼尿肌压力、逼尿肌漏点压力和平均尿道压力。大多数患者在平均 4-9 个月后需要再次注射。BoNT-A 与任何重大不良事件无关,可能改善生活质量以及逼尿肌外括约肌协同失调的尿动力学参数。